Aura Biosciences (AURA) Invested Capital (2020 - 2026)
Aura Biosciences filings provide 7 years of Invested Capital readings, the most recent being $107.2 million for Q1 2026.
- Quarterly Invested Capital fell 16.19% to $107.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $107.2 million through Mar 2026, down 16.19% year-over-year, with the annual reading at $136.9 million for FY2025, 9.91% down from the prior year.
- Invested Capital hit $107.2 million in Q1 2026 for Aura Biosciences, down from $136.9 million in the prior quarter.
- Across five years, Invested Capital topped out at $225.8 million in Q4 2023 and bottomed at $107.2 million in Q1 2026.
- Average Invested Capital over 5 years is $160.9 million, with a median of $156.7 million recorded in 2025.
- The largest annual shift saw Invested Capital skyrocketed 223.55% in 2022 before it tumbled 38.71% in 2025.
- Aura Biosciences' Invested Capital stood at $195.6 million in 2022, then rose by 15.47% to $225.8 million in 2023, then plummeted by 32.71% to $152.0 million in 2024, then dropped by 9.91% to $136.9 million in 2025, then dropped by 21.67% to $107.2 million in 2026.
- Per Business Quant, the three most recent readings for AURA's Invested Capital are $107.2 million (Q1 2026), $136.9 million (Q4 2025), and $156.7 million (Q3 2025).